| HOME >> BIOLOGY >> TECHNOLOGY |
Minority interest income (loss),
net of taxes 1 - 1 (2)
Net earnings from continuing
operations 57 46 80 59
Net loss from discontinued
operations, net of taxes - (1) - (2)
Net earnings $57 $45 $80 $57
Earnings per common share - diluted:
Earnings per common share -
continuing operations $0.52 $0.42 $0.73 $0.54
Loss per common share - discontinued
operations - (0.01) - (0.02)
Net earnings per common share -
diluted $0.52 $0.41 $0.73 $0.52
Weighted average shares - assuming
dilution 109 108 109 108
Stock-based compensation expense:
Cost of sales $3 $2 $5 $4
Selling, general and administrative 5 5 8 8
Research and development 2 1 3 3
Total stock-based compensation
expense $10 $8 $16 $15
$ in millions As of As of
June 30, Dec. 31,
2008 2007
Cash & cash equivalents $513 $246
Marketable securities - current 34 288
Account receivable, net 580 497
Other receivables 98 86
Inventories 471 454
Marketable securities - long-term 21 17
Accounts payable & accrued
liabilities 442 443
Working capital
'/>"/>
| SOURCE Barr Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |